AR073283A1 - Derivados de heteroarilamida y su uso como activadores de glucokinasa - Google Patents

Derivados de heteroarilamida y su uso como activadores de glucokinasa

Info

Publication number
AR073283A1
AR073283A1 ARP090103462A ARP090103462A AR073283A1 AR 073283 A1 AR073283 A1 AR 073283A1 AR P090103462 A ARP090103462 A AR P090103462A AR P090103462 A ARP090103462 A AR P090103462A AR 073283 A1 AR073283 A1 AR 073283A1
Authority
AR
Argentina
Prior art keywords
alkyl
halo
alkylamino
optionally substituted
independently
Prior art date
Application number
ARP090103462A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41228587&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR073283(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of AR073283A1 publication Critical patent/AR073283A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41551,2-Diazoles non condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18One oxygen or sulfur atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38Nitrogen atoms
    • C07D231/40Acylated on said nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Composiciones farmacéuticas de los mismos; y métodos para tratar enfermedades, trastornos o afecciones mediadas por glucoquinasa. Reivindicacion 1: Un compuesto de formula (1) en la que cada uno de X, Y, y Z es independientemente C(R ) o N, donde R es H, halo, alquilo C1-3, halo-sustituido, alquilo C1-6 o alcoxi C1-6, y X, Y y Z no son todos N; R1 es H, alquilo C1-6, alquilo C1-3 halo-sustituido, -S(O)2(R1a) o C(O)R1a, donde R1a es alquilo C1-6, cicloalquilo C3-6, alquilamino C1-3 o dialquilamino C1-3; R2 es cicloalquilo C3-6 o heterociclo de 5 a 6 miembros que contiene un heteroátomo de N, O o S; donde dicho cicloalquilo y dicho heterociclo están opcionalmente sustituidos con uno a dos sustituyentes, siendo cada uno independientemente halo, alquilo C1-6, alcoxi C1-6, -CF3 o ciano; R3 es H o alquilo C1-6; y R4 es quinolinilo, tiazolo[5,4-b]piridinilo o heteroarilo de 5 a 6 miembros que contiene de uno a dos heteroátomos N y opcionalmente un heteroátomo O o S, donde dichos heteroarilo, quinolinilo y tiazolo[5,4-b]piridinilo están opcionalmente sustituidos con uno a dos R4a, donde cada R4a es independientemente alquilo C1-6 opcionalmente sustituido con uno a tres hidroxi, -CF3, ciano, alcoxi C1-6, halo, amino, alquilamino C1-3, di-alquilamino C1-3, -CO2R4b, -alquil C1-6-CO2R4b, -C(O)N(R4b)2, -P(O)(OR4)2, -alquil C1-6-P(O)(OR4b)2, -P(O)(OR4b)-alquilo C1-3, alquilsulfonilo C1-3, -SO3H, -NHC(O)R4c o arilalquilo C1-6, donde el arilo de dicho arilalquilo está opcionalmente sustituido con alquilo C1-6, -CF3 ciano, alcoxi C1-6, halo, amino, alquilamino C1-3 o di-alquilamino C1-3; R4b en cada caso es independientemente hidrogeno, alquilo C1-6 o bencilo; y R4c en cada caso es independientemente CO2H o alquilo C1-6 opcionalmente sustituido con uno a tres hidroxi; o una sal farmacéuticamente aceptable del mismo.
ARP090103462A 2008-09-11 2009-09-09 Derivados de heteroarilamida y su uso como activadores de glucokinasa AR073283A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9605608P 2008-09-11 2008-09-11
US23257809P 2009-08-10 2009-08-10

Publications (1)

Publication Number Publication Date
AR073283A1 true AR073283A1 (es) 2010-10-28

Family

ID=41228587

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090103462A AR073283A1 (es) 2008-09-11 2009-09-09 Derivados de heteroarilamida y su uso como activadores de glucokinasa

Country Status (29)

Country Link
US (4) US7977367B2 (es)
EP (1) EP2344458A1 (es)
JP (2) JP4907746B2 (es)
KR (1) KR101258331B1 (es)
CN (1) CN102216276A (es)
AP (1) AP2011005613A0 (es)
AR (1) AR073283A1 (es)
AU (1) AU2009290474A1 (es)
BR (1) BRPI0918128A2 (es)
CA (1) CA2735184C (es)
CL (1) CL2011000478A1 (es)
CO (1) CO6361937A2 (es)
CR (1) CR20110103A (es)
DO (1) DOP2011000076A (es)
EA (1) EA201100311A1 (es)
EC (1) ECSP11010885A (es)
GE (1) GEP20135793B (es)
IL (1) IL211411A0 (es)
MA (1) MA32627B1 (es)
MX (1) MX2011002613A (es)
NI (1) NI201100050A (es)
NZ (1) NZ591366A (es)
PA (1) PA8842101A1 (es)
PE (1) PE20110303A1 (es)
SV (1) SV2011003855A (es)
TW (1) TWI382026B (es)
UY (1) UY32098A (es)
WO (1) WO2010029461A1 (es)
ZA (1) ZA201101364B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2454229B1 (en) * 2009-05-06 2017-09-13 Risen (Shanghai) Pharma Tech Co, Ltd. Amino acid derivatives for the treatment of neuropathic pain
EP2553086B1 (en) 2010-03-31 2017-04-19 The Scripps Research Institute Reprogramming cells
EP2638016B1 (en) * 2010-11-11 2014-10-01 Sanofi Process for the preparation of 3-(6-amino-pyridin-3yl)-2-acrylic acid derivatives
US9055750B2 (en) 2012-02-03 2015-06-16 Basf Se Fungicidal pyrimidine compounds
WO2013113781A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds i
WO2013113776A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013113773A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
CA2862346A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013113782A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013113787A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013113719A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds ii
WO2013113716A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
AU2013231392A1 (en) 2012-03-13 2014-10-02 Basf Se Fungicidal pyrimidine compounds
WO2013135672A1 (en) 2012-03-13 2013-09-19 Basf Se Fungicidal pyrimidine compounds
US9096528B2 (en) 2012-07-04 2015-08-04 Agro-Kanesho Co., Ltd. 2-aminonicotinic acid ester derivative and bactericide containing same as active ingredient
WO2014142255A1 (ja) 2013-03-14 2014-09-18 武田薬品工業株式会社 複素環化合物
JP6411342B2 (ja) 2013-07-03 2018-10-24 武田薬品工業株式会社 アミド化合物
WO2015002231A1 (ja) 2013-07-03 2015-01-08 武田薬品工業株式会社 複素環化合物
EP2878339A1 (en) 2013-12-02 2015-06-03 Siena Biotech S.p.A. SIP3 antagonists
AR099677A1 (es) 2014-03-07 2016-08-10 Sumitomo Chemical Co Compuesto heterocíclico fusionado y su uso para el control de plagas
CN109715637B (zh) 2016-07-22 2022-04-05 百时美施贵宝公司 葡萄糖激酶激活剂及其使用方法
TW201840578A (zh) * 2017-02-22 2018-11-16 以色列商亞當阿甘公司 製備甲基膦酸丁基酯的方法
GB201714777D0 (en) 2017-09-14 2017-11-01 Univ London Queen Mary Agent
CN109134535B (zh) * 2018-10-22 2021-03-19 江苏长青农化股份有限公司 一种甲基磷酸酯的制备方法
WO2022043322A1 (en) * 2020-08-25 2022-03-03 Helmholtz-Zentrum für Infektionsforschung GmbH INHIBITORS OF PSEUDOMONAS AERUGINOSA VIRULENCE FACTOR LasB
MX2024000322A (es) 2021-07-08 2024-01-25 Ishihara Sangyo Kaisha Composicion nematicida.

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5795984A (en) 1980-12-05 1982-06-15 Tanabe Seiyaku Co Ltd Pyridinecarboxamide derivative and its preparation
US5399564A (en) 1991-09-03 1995-03-21 Dowelanco N-(4-pyridyl or 4-quinolinyl) arylacetamide and 4-(aralkoxy or aralkylamino) pyridine pesticides
BR9305569A (pt) 1992-07-03 1995-12-26 Kumiai Chemical Industry Co Derivados heterocíclicos condensados e herbicidas
US6121274A (en) 1994-07-22 2000-09-19 Byk Gulden Lomberg Chemische Fabrik Gmbh Dihydrobenzofurane
DE4434637A1 (de) 1994-09-28 1996-04-04 Hoechst Schering Agrevo Gmbh Substituierte Pyridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel und Fungizide
MX9702734A (es) 1994-10-13 1997-06-28 Pfizer Benzopirano y compuestos benzocondensados, su preparacion y su uso como antagonistas de leucotrieno b4 (ltb4).
RU2128655C1 (ru) 1994-10-13 1999-04-10 Пфайзер Инк. Бензопирановые и бензоконденсированные соединения, промежуточные соединения, фармацевтическая композиция и способ ингибирования
DE19603576A1 (de) 1996-02-01 1997-08-07 Bayer Ag Acylierte 4-Amino und 4-Hydrazinopyrimidine
CA2252537A1 (en) 1996-05-20 1997-11-27 Darwin Discovery Limited Benzofuran carboxamides and their therapeutic use
DE69717827T2 (de) 1996-08-19 2003-09-04 Altana Pharma Ag Benzofuran-4-carboxamide
JP2002502851A (ja) 1998-02-09 2002-01-29 ダーウィン・ディスカバリー・リミテッド ベンゾフラン−4−カルボキサミドとその治療的使用
ATE377003T1 (de) 1999-01-22 2007-11-15 Elan Pharm Inc Verbindungen die die vla-4 vermittelte adhäsion von leukozyten inhibieren
SE9901573D0 (sv) 1999-05-03 1999-05-03 Astra Ab New compounds
US6777446B2 (en) 2000-09-05 2004-08-17 Tularik, Inc. FXR modulators
CA2436854A1 (en) 2000-11-20 2002-05-23 Bristol-Myers Squibb Company Pyridone derivatives as ap2 inhibitors
WO2002046173A1 (en) * 2000-12-06 2002-06-13 F. Hoffmann-La Roche Ag Fused heteroaromatic glucokinase activators
US6482951B2 (en) * 2000-12-13 2002-11-19 Hoffmann-La Roche Inc. Isoindolin-1-one glucokinase activators
CA2433090A1 (en) 2000-12-27 2002-07-04 Kyowa Hakko Kogyo Co., Ltd. Dipeptidyl peptidase iv inhibitor
JPWO2002100833A1 (ja) 2001-06-12 2004-09-24 住友製薬株式会社 Rhoキナーゼ阻害剤
SE0102300D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
EP1444204A4 (en) 2001-10-22 2009-11-04 Univ New York State Res Found PROTEIN KINASE AND PHOSPHATASE INHIBITORS, METHOD FOR THEIR DEVELOPMENT, AND METHOD FOR THEIR USE
CN100486576C (zh) 2002-02-14 2009-05-13 法玛西雅公司 作为p38map激酶调节剂的取代吡啶酮类
CN100357283C (zh) 2002-04-02 2007-12-26 中国科学院上海药物研究所 一类甲硫氨酰氨肽酶抑制剂
AU2003236247A1 (en) 2002-05-03 2003-11-17 Warner-Lambert Company Llc Bombesin antagonists
BR0311707A (pt) 2002-06-13 2005-03-15 Du Pont Composto, composição e método de controle de pelo menos uma praga invertebrada
GB0226930D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
EP1433778A1 (en) 2002-12-23 2004-06-30 Jerini AG Use of nitriles as rotamase inhibitors
JP4621198B2 (ja) * 2003-02-11 2011-01-26 プロシディオン・リミテッド トリ(シクロ)置換アミドグルコキナーゼ活性化化合物
BRPI0407283A (pt) 2003-02-13 2006-01-31 Banyu Pharma Co Ltd Composto, composição farmacêutica, e, agente ativador de glucoquinase, agentes terapêuticos e/ou agentes preventivos para diabetes melito e obesidade
CL2004000303A1 (es) 2003-02-20 2005-04-08 Tibotec Pharm Ltd Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih.
KR20050105488A (ko) 2003-02-26 2005-11-04 반유 세이야꾸 가부시끼가이샤 헤테로아릴카바모일벤젠 유도체
MXPA06000538A (es) 2003-07-15 2006-03-30 Smithkline Beecham Corp Compuestos novedosos.
JP4727578B2 (ja) 2003-08-01 2011-07-20 中外製薬株式会社 マロニル−CoAデカルボキシラーゼ阻害剤として有用な複素環式化合物
NL1026826C2 (nl) 2003-08-13 2007-01-04 Pharmacia Corp Gesubstitueerde pyridinonen.
EP1532980A1 (en) * 2003-11-24 2005-05-25 Novo Nordisk A/S N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes
SE0303480D0 (sv) 2003-12-19 2003-12-19 Biovitrum Ab Benzofuranes
BRPI0509573A (pt) * 2004-04-02 2007-09-25 Novartis Ag derivados de sulfonamida-tiazolpiridina como ativadores de glicocinase úteis para o tratamento de diabetes do tipo 2
CN1993347A (zh) 2004-07-29 2007-07-04 默克公司 钾通道抑制剂
JP2008511659A (ja) 2004-09-01 2008-04-17 ライジェル ファーマシューティカルズ, インコーポレイテッド 2,4−ピリミジンジアミン化合物の合成
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
SE0403006D0 (sv) 2004-12-09 2004-12-09 Biovitrum Ab New compounds
WO2006066746A1 (en) 2004-12-21 2006-06-29 F. Hoffmann-La Roche Ag Chroman derivatives and their use as 5-ht receptor ligands
JP4167218B2 (ja) 2004-12-22 2008-10-15 株式会社メタル建材 薄板用タッピンねじ
TW200700392A (en) 2005-03-16 2007-01-01 Astrazeneca Ab Novel compounds
EP1869052A1 (en) 2005-04-06 2007-12-26 AstraZeneca AB Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors
US7754717B2 (en) 2005-08-15 2010-07-13 Amgen Inc. Bis-aryl amide compounds and methods of use
US20090281142A1 (en) 2005-08-31 2009-11-12 Astellas Pharma Inc. Thiazole derivative
JP2009013065A (ja) 2005-10-14 2009-01-22 Astellas Pharma Inc 縮合へテロ環化合物
US20090215801A9 (en) 2005-11-15 2009-08-27 Astrazeneca Ab, Sodertaije, Swedenastex Thereapeutics Ltd Novel 2-Aminopyrimidinone Derivatives And Their Use
EP2001875A2 (en) 2006-03-08 2008-12-17 Takeda San Diego, Inc. Glucokinase activators
WO2007117995A2 (en) 2006-03-30 2007-10-18 Takeda San Diego, Inc. Kinase inhibitors
US7842713B2 (en) 2006-04-20 2010-11-30 Pfizer Inc Fused phenyl amido heterocyclic compounds
EP2091947A2 (en) 2006-12-20 2009-08-26 Takeda San Diego, Inc. Glucokinase activators
JP2010138073A (ja) 2007-03-30 2010-06-24 Taisho Pharmaceutical Co Ltd ピコリン酸アミド化合物
US8299115B2 (en) 2007-06-08 2012-10-30 Debnath Bhuniya Pyrrole-2-carboxamide derivatives as glucokinase activators, their process and pharmaceutical application
EA018988B1 (ru) * 2008-05-16 2013-12-30 Такеда Калифорния, Инк. Активаторы глюкокиназы
EP2389374A1 (en) 2009-01-20 2011-11-30 Pfizer Inc. Substituted pyrazinone amides

Also Published As

Publication number Publication date
AU2009290474A1 (en) 2010-03-18
JP4907746B2 (ja) 2012-04-04
TW201010998A (en) 2010-03-16
US7977367B2 (en) 2011-07-12
IL211411A0 (en) 2011-05-31
NI201100050A (es) 2011-09-27
KR101258331B1 (ko) 2013-04-26
US8389552B2 (en) 2013-03-05
CN102216276A (zh) 2011-10-12
US20110230445A1 (en) 2011-09-22
CR20110103A (es) 2011-03-14
JP5225452B2 (ja) 2013-07-03
CA2735184C (en) 2013-05-28
JP2012502091A (ja) 2012-01-26
BRPI0918128A2 (pt) 2015-11-24
ZA201101364B (en) 2012-04-25
US20130165452A1 (en) 2013-06-27
PA8842101A1 (es) 2010-04-21
DOP2011000076A (es) 2011-03-31
EP2344458A1 (en) 2011-07-20
CA2735184A1 (en) 2010-03-18
US20100063063A1 (en) 2010-03-11
US20120225910A1 (en) 2012-09-06
TWI382026B (zh) 2013-01-11
US8329920B2 (en) 2012-12-11
SV2011003855A (es) 2011-05-16
CO6361937A2 (es) 2012-01-20
JP2012092115A (ja) 2012-05-17
EA201100311A1 (ru) 2011-10-31
MX2011002613A (es) 2011-05-23
MA32627B1 (fr) 2011-09-01
ECSP11010885A (es) 2011-04-29
PE20110303A1 (es) 2011-05-21
AP2011005613A0 (en) 2011-04-30
WO2010029461A1 (en) 2010-03-18
UY32098A (es) 2010-04-30
KR20110043748A (ko) 2011-04-27
NZ591366A (en) 2012-05-25
GEP20135793B (en) 2013-03-25
CL2011000478A1 (es) 2011-06-17

Similar Documents

Publication Publication Date Title
AR073283A1 (es) Derivados de heteroarilamida y su uso como activadores de glucokinasa
AR067757A1 (es) Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales.
CO6612267A2 (es) Nuevos derivados de 1,1 dióxido- 5 fenil- 2,3,4-5tetrahidro- 1,4-benzotiazepina y composiciones farmaceúticas que los comprenden
PE20140970A1 (es) Derivados de 6-ciclobutil-1,5-dihidro-pirazol [3,4-d) pirimidin-4-ona y su uso como inhibidores de pde9a
AR070469A1 (es) Derivados de naftiridina y composiciones farmaceuticas como inhibidores de quinasa con actividad sobre c- kit y pdgfr
PE20191613A1 (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret
AR073138A1 (es) Derivados de dioxa-biciclo (3.2.1) octano- 2,3,4-triol
PE20220139A1 (es) Compuestos de tioeno[3,2-b] piridin-7-amina para tratar la disautonomia familiar
ECSP088871A (es) Derivados de triazolopirazina
PE20061198A1 (es) Derivados de pirazol como inhibidores de cdk y gsk
AR075729A1 (es) Derivados de benzofuranilo, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de la obesidad y/o diabetes.
SV2011004077A (es) Derivados aminobutiricos sustituidos como inhibidores de neprilisina
PE20141205A1 (es) Spiro-[1,3]-oxacinas y spiro-[1,4]-oxacepinas como inhibidores de bace1 y/o bace2
CO6321265A2 (es) Compuestos de 2-amido-3-metil pirrolo pirimidinona fenilo -sustituidos como inhibidores bace-1 composiciones y su uso
MX2012004311A (es) Derivados de ciclohexano spiro condensados como inhibidores de lipasa sensible a hormonas (hsl) utiles en el tratamiento de diabetes.
AR057131A1 (es) Derivados de purina como inmunomodulador
PE20161552A1 (es) Compuestos de dihidroisoquinolinona sustituida
ECSP088225A (es) 1h-imidazopiridinas sustituidas con hidroxi y procedimientos
BR112014001468A2 (pt) compostos de tetra-hidropirido-piridina e tetra-hidropirido-pirimidina e uso dos mesmos como modulares do receptor c5a
NI200900219A (es) DERIVADOS DE BENCIMIDAZOL Caso: PC 33611A
DOP2012000144A (es) Procedimiento para la preparacion de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}metilcarbamato de metilo y su purificacion para su uso como principio activo farmaceutico
NO20092224L (no) Quiniklidinderivater av (hetero)arylcykloheptankarboksylsyre som muskarinreseptorantagonister
UY31638A1 (es) Furo[3,2-c]piridina y tieno[3,2-c]piridinas
GT200600081A (es) Derivados de acetilenno
PE20110122A1 (es) COMPUESTOS DERIVADOS DE 9H-PIRROLO[2,3-b:5,4-c]DIPIRIDIN-6-(PIRIDIN-3-IL) COMO INHIBIDORES DE LAS CINASA Pim

Legal Events

Date Code Title Description
FA Abandonment or withdrawal